GENETIC DIVERSITY OF HEPATITIS C VIRUS

丙型肝炎病毒的基因多样性

• 批准号: 3770429
• 负责人: S NEDJAR
• 金额: --
• 依托单位: BUREAU OF HEALTH PLANNING AND RESOURCES DEVELOPMENT
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3770429
• 关键词: genetic polymorphism; genome; hepatitis C virus; human tissue; serum; structural genes; virus genetics

Hepatitis C virus (HCV) is the etiologic agent in the majority of cases of transfusion associated hepatitis (TAH) in the United States. HCV disease can also be contracted by intravenous or percutaneous blood exposure such as intravenous drug abuse, and occupational exposure to blood borne pathogens. Initiative to reduce the incidence of the disease include donor blood testing, and research on vaccines. The former has already resulted in a reduction of the risk of transmission of HCV. The development of an effective vaccine is hampered by the genetic diversity of the virus. As evidence for this diversity accumulates, it appears that strains of the virus ( at least 4 of which have been described in the U.S., Japan and Eurasia), while the second is the evolutionary change which occur in a strain over time. The later is the subject of this study. The investigators propose to obtain stored sera of 30 to 50 persons who have been referred for testing for HCV on more than one occasion. Positive screening tests are often repeated within six months. A comparative analysis of preselected structural regions in the genome for variation between the first and subsequent samples will be done on sample with positive confirmatory tests. It is hypothesized that the observed changes will not be random. A better understanding of the process will further the vaccine and treatment initiative on HCV.

丙型肝炎病毒（HCV）是大多数病例的病原体， 输血相关性肝炎（TAH）在美国HCV病 也可通过静脉内或经皮血液暴露而收缩， 静脉注射药物滥用和职业暴露于血液传播 病原体 减少该病发病率的倡议包括捐助者 血液检测和疫苗研究。 前者已经导致 降低HCV传播的风险。 制定一项 有效的疫苗受到病毒遗传多样性的阻碍。 作为 这种多样性的证据积累，似乎菌株的 病毒（其中至少4种已在美国描述，日本和 第二种是发生在一个 随着时间的推移而应变。 后者是本研究的主题。 研究人员建议获得30至50人的储存血清， 曾多次被转介接受HCV检测。积极 筛查测试通常在六个月内重复进行。 比较 分析基因组中预先选定的结构区域的变异 第一个和后续样品之间的测试将在样品上进行， 阳性确认测试。 据推测，观察到的变化 不会是随机的 更好地了解这一进程将进一步促进 疫苗和治疗计划。